Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesLaboratory/PathologyCapital Bluecross vaginitis testing Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentCapital BluecrossPolicy AHS - M2057

    Diagnosis of Vaginitis

    Customize your policy alerts

    Sign up for Capital Bluecross Policy AHS - M2057 alerts

    Get alerted when Policy AHS - M2057 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage criteria for laboratory and point-of-care testing used to diagnose causes of vaginitis (BV, VVC, trichomoniasis and related testing) for Capital Bluecross members.

    Policy Summary
    PayerCapital Bluecross
    PolicyDiagnosis of Vaginitis
    Policy CodePolicy AHS - M2057
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionDocument signs and symptoms of vaginitis when ordering diagnostic testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3common causes (BV, VVC, TV)
    7coverage rules
    7 daysminimum retest interval
    5FDA-cleared multiplex NAATs cited
    ~named vendor tests

    Coverage Criteria for Vaginitis Testing

    Covered diagnostic tests for symptomatic vaginitis

    Covered when criteria below are met for individuals with signs and symptoms of vaginitis

    Basic office/lab tests: pH testing; amine (KOH/whiff) test; measurement of sialidase activity; saline wet mount; KOH wet mount; microscopic examination of vaginal fluids

    Meets coverage criteria for symptomatic individuals

    Direct probe DNA tests: Direct probe DNA–based identification of Gardnerella, Trichomonas, and Candida (e.g., BD Affirm VPIII)

    Meets coverage criteria for symptomatic individuals

    Culture for Candida: Vaginal cultures for Candida species when symptomatic individuals have negative wet-mounts and normal pH

    Meets coverage criteria

    Policy Summary
    PayerCapital Bluecross
    PolicyDiagnosis of Vaginitis
    Policy CodePolicy AHS - M2057
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionDocument signs and symptoms of vaginitis when ordering diagnostic testing.
    SourceLink
    On This Page
    Coverage Criteria for Vaginitis TestingCovered Indications and Diagnostic UsesTests and Uses Not CoveredProcedure and Test CodesProvider Actions, Documentation, and Billing GuidanceTesting Frequency and Repeat IntervalsOrdering Requirements and Specimen GuidanceBackground and Clinical ContextDefinitions and Test TermsPolicy Revision History
    PCR for complicated VVC: Qualitative PCR–based identification of Candida to confirm diagnosis and identify non‑albicans Candida for complicated vulvovaginal candidiasis

    Meets coverage criteria

    BV-specific NAAT: NAAT specific to BV (e.g., Aptima BV; OneSwab BV Panel PCR with Lactobacillus profiling; SureSwab Advanced BV, TMA) or single/multitarget PCR testing for BV

    Meets coverage criteria for symptomatic individuals with BV signs

    NAAT vaginitis panels: NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis) (e.g., BD MAX Vaginal Panel, NuSwab VG, Xpert Xpress MVP)no more than one test every 7 days

    Meets coverage criteria for symptomatic individuals

    Indications for molecular or syndromic vaginitis testing

    Covered when ALL of the following are met

    Symptomatic presentation: Patient has vaginal symptoms such as discharge, odor, or itch

    CDC: BV NAATs should be used among symptomatic women only

    Clinical evaluation documented: Provider documents history, physical examination, and basic in‑office tests as available (vaginal pH, KOH/amine test, microscopy)

    CDC recommends careful history and laboratory testing to determine etiology

    Medically necessary diagnostic testing for symptomatic vaginitis

    Covered testing when ALL of the following are met

    Symptom requirement: Patient presents with symptoms consistent with vaginitis (e.g., vaginal discharge, odor, or pruritus)

    CDC and IDSA: multiplex NAATs and NAATs intended for symptomatic women and not for asymptomatic screening

    Appropriate test selection: Use of Amsel clinical criteria, Nugent Gram stain, point‑of‑care tests (pH, KOH wet mount, sialidase activity) or molecular multiplex NAAT panels is acceptable for symptomatic diagnosis

    Guidelines note traditional methods are useful and multiplex NAATs have higher sensitivity and detect coinfections

    Specimen type and platform: Specimen is a clinician‑ or self‑collected vaginal swab validated for the chosen assay/platform

    FDA‑cleared assays and LDTs specify use of clinician‑ or patient‑collected vaginal swabs; confirm platform intended use

    Screening asymptomatic individuals for trichomoniasis or bacterial vaginosis, including asymptomatic pregnant individuals at average or high risk for preterm labor, does not meet coverage criteria. Documentation and testing should be limited to individuals with signs or symptoms of vaginitis (e.g., discharge, odor, pruritus) as described in the policy.

    Molecular-based panel testing intended to evaluate vaginal flora imbalance or infertility (for example, comprehensive multi-organism assays such as AMPLISwab™ when used for these broader indications) does not meet coverage criteria due to insufficient evidence that such testing is required or beneficial for diagnosis or treatment in these contexts.

    Broad molecular or multiplex panels that concurrently test for vaginitis and a range of other sexually transmitted infections or genital pathogens (i.e., multi‑purpose panels beyond the vaginitis-specific indications) do not meet coverage criteria and are not covered when used outside the specific symptomatic vaginitis indications described in this policy.

    Routine screening for bacterial vaginosis (BV) among asymptomatic pregnant women for the purpose of preventing preterm birth is not recommended by the CDC and USPSTF; therefore, such routine screening is not supported for coverage under this policy.

    Routine screening of asymptomatic pregnant persons for BV is not recommended by guideline bodies (CDC, USPSTF) and is not appropriate for testing with multiplex NAATs or other assays in the absence of additional risk factors or clinical indications.

    Procedure and proprietary test codes listed in this medical policy are provided only as a general reference for billing and documentation. The lists may not be exhaustive; providers should confirm the correct CPT/HCPCS or proprietary test identifiers when submitting claims.

    NAAT testing for Candida species that is not specifically described as covered by the policy (for example, quantitative Candida NAATs outside the defined indications) does not meet coverage criteria and will be denied when submitted without an allowed indication.

    The use of BV NAATs in asymptomatic women is not supported because accuracy in asymptomatic populations is not well defined; guideline statements recommend BV NAATs be used among symptomatic women only, and use outside that context is not recommended.

    Multiplex NAAT panels intended for symptomatic diagnosis are not appropriate for routine asymptomatic screening or for use as a test‑of‑cure or prognostic test. Use of these panels for asymptomatic screening (including in pregnant individuals without risk factors) or as routine test‑of‑cure purposes does not meet coverage criteria.

    Covered Indications and Diagnostic Uses

    Testing to diagnose causes of symptomatic vaginitis (BV, VVC, trichomoniasis) using targeted methods

    Targeted diagnostic methods: pH and amine (KOH) testing; sialidase activity point‑of‑care testing (e.g., OSOM BVBlue); saline and KOH wet mounts with microscopic examination

    Accepted targeted, low‑cost diagnostic modalities for symptomatic patients

    Targeted molecular/probe tests: Direct probe DNA or amplified probe testing for individual organisms (e.g., Affirm VP III; probes/NAATs for Gardnerella, Candida, Trichomonas)

    Accepted targeted molecular identification methods

    Culture and organism identification: Vaginal culture for Candida species when indicated and culture‑based identification (including probe confirmation) per VVC guidance

    Culture indicated for symptomatic patients with negative microscopy or for complicated/recurrent VVC

    Molecular NAAT/PCR/TMA for symptomatic vaginitis: Single‑target NAATs for Gardnerella, Candida, or Trichomonas or multiplex NAAT/PCR/TMA panels (e.g., Aptima CV/TV, Aptima BV, SureSwab Advanced Vaginitis, BD MAX Vaginal Panel) for symptomatic womenno more than one test every 7 days for NAAT panels

    Multiplex molecular panels accepted for symptomatic diagnosis; document symptoms and specimen type

    Symptomatic evaluation using molecular/NAAT panels

    Multiplex NAAT panel examples: Commercial symptomatic NAAT/molecular panels include Aptima CV/TV and Aptima BV (Hologic), SureSwab Advanced Vaginitis (Quest), SureSwab Advanced Vaginitis Plus (adds Chlamydia/GC), and BD MAX Vaginal Panel

    These assays detect combinations of BV, Candida species, and Trichomonas from a single vaginal swab for symptomatic women

    Panel targets: Panels commonly target Candida species (including C. albicans group and C. glabrata), Trichomonas vaginalis, and BV‑associated bacteria (G. vaginalis, A. vaginae, Lactobacillus profiling)

    Designed to identify coinfections and improve diagnostic sensitivity compared with clinical diagnosis alone

    Symptomatic vaginitis with clinical presentation consistent with vaginitis

    Use of multiplex NAATs vs traditional methods: For symptomatic patients whose clinical presentation is consistent with vaginitis, multiplex NAATs and traditional diagnostic methods (Amsel, Nugent, wet mount) are appropriate; NAATs detect multiple targets and coinfections

    NAATs provide higher sensitivity and may be used when microscopy/pH/KOH are unavailable or as adjuncts; tests intended for symptomatic use

    Clinical presentation requirement: Clinical history and examination should support the diagnosis of vaginitis (discharge, odor, itch) when ordering multiplex NAATs

    Document symptomatic presentation and appropriate specimen type (clinician‑ or self‑collected vaginal swab)

    Complicated or recurrent VVC

    Indication for culture or PCR: Complicated or recurrent vulvovaginal candidiasis (VVC) — obtain vaginal culture or PCR to confirm diagnosis and to identify non‑albicans Candida species

    Per CDC and IDSA guidance; informs targeted therapy when empiric treatment fails or infections recur

    When to escalate testing: If microscopy is negative but symptoms persist or when treatment failure/recurrent episodes occur, perform culture or qualitative PCR to identify species-level Candida

    Culture or PCR recommended to identify non‑albicans Candida that may require different therapy

    Diagnosis of BV, VVC, and trichomoniasis using appropriate molecular, culture, enzymatic, or microscopic tests

    Covered when testing is ordered to diagnose BV, VVC, or trichomoniasis using appropriate methods

    Appropriate diagnostic modalities: Diagnosis of bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis using molecular NAAT/PCR/TMA panels, targeted NAATs/probes, culture, enzymatic (sialidase) point‑of‑care tests, or microscopic wet‑mount examination

    Use modality appropriate to clinical presentation; NAAT panels reported per organism or algorithmic BV result

    Panel reporting: Molecular/panel tests reported as positive or negative for each organism or as an algorithmic result for likelihood of bacterial vaginosis (e.g., CPT 81513 descriptions)

    Refer to applicable CPT/proprietary test reporting conventions for documentation and billing

    Tests and Uses Not Covered

    Molecular panels intended for assessing vaginal flora imbalance or infertility and broad multi‑purpose panels (for example, AMPLISwab™ when used beyond covered vaginitis indications) are not covered. These comprehensive multi‑organism assays are not supported for these indications due to lack of evidence demonstrating clinical benefit for diagnosis or treatment in this context.

    Culture of Gardnerella vaginalis is not recommended as a diagnostic tool for bacterial vaginosis because culture lacks specificity and does not have a role in the diagnosis of BV per guideline statements.

    Cervical Pap tests or cytology have no clinical utility for diagnosing bacterial vaginosis due to low sensitivity and specificity, and therefore are not appropriate diagnostic tests for BV.

    The use of multiplex NAAT panels for asymptomatic screening, including routine screening of asymptomatic pregnant women without risk factors, and the use of these assays as a test‑of‑cure or for prognostic purposes does not meet coverage criteria and is not intended per guideline recommendations.

    Procedure codes shown in the policy are provided for reference and may not be all‑inclusive. The policy text does not by itself list every test that is not covered; providers should verify coverage and coding for specific assays prior to ordering.

    Procedure and Test Codes

    Applicable CPT/HCPCS procedure codesmixed
    No codes listed
    Covered CPT Codes (molecular BV/vaginitis panels)CPTCovered
    81513Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, algorithm reported as a positive or negative result for bacterial vaginosis
    Covered CPT Codes (POCT, culture, probe, microscopy)CPTCovered
    82120Amines, vaginal fluid, qualitative
    83986pH; body fluid, not otherwise specified
    87070Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates
    87149Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate
    87150Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate
    87210Smear, primary source with interpretation; wet mount for infectious agents (e.g., saline, India ink, KOH preps)
    87480Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique
    87481Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique
    87482Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification
    87510Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique
    1–10 of 13
    1/2
    Covered CPT Codes (molecular assays referenced)CPT
    81513Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species
    Covered CPT Codes (traditional microbiology and targeted NAAT)CPTCovered
    82120Amines, vaginal fluid, qualitative
    83986pH; body fluid, not otherwise specified
    87070Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates
    87149Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe
    87150Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe
    87210Smear, primary source with interpretation; wet mount for infectious agents (e.g., saline, India ink, KOH preps)
    87480Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique
    87481Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique
    87482Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification
    87510Infectious agent detection by nucleic acid (DNA or RNA); Gardnerella vaginalis, direct probe technique
    1–10 of 13
    1/2
    Covered CPT/Proprietary Codes (not otherwise specified & proprietary panels)mixed
    87797Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; direct probe technique, each organism
    87798Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism
    87799Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; quantification, each organism
    87905Infectious agent enzymatic activity other than virus (e.g., sialidase activity in vaginal fluid)
    0068UCandida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species
    0330UIdentification of 27 organisms, amplified probe technique, vaginal swab
    0505UInfectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism
    Panel reporting — result format
    Reporting formatPanel/multiplex NAAT and proprietary panels are reported as positive or negative for each organism or as an algorithm-derived result indicating likelihood of bacterial vaginosis (e.g., CPT 81513 algorithm result for BV).
    Example CPT referenceCPT 81513: algorithm reported as a positive or negative result for bacterial vaginosis (reports organism detection and algorithmic BV likelihood).
    Panel scopePanels may include separate detection of BV-associated targets (e.g., Gardnerella, Atopobium, BVAB2, Megasphaera) and may also report Trichomonas and Candida species where applicable.
    Specimen typeVaginal-fluid specimens (clinician- or patient-collected) are used for assays reported per organism or algorithm.

    Provider Actions, Documentation, and Billing Guidance

    Billing Rule

    NAAT panel frequency limit — 1 test per 7 days

    NAAT-based multiplex vaginitis panel testing is limited to no more than one panel test within any 7‑day period; order repeat NAAT panel testing only after the minimum treatment window has passed or per the policy exceptions (see Note 1).

    Prior Authorization

    Prior authorization / ordering: document symptomatic presentation

    When ordering syndromic/multiplex PCR or NAAT panels, document that the patient is symptomatic (vaginal discharge, odor, itch, burning) because syndromic PCR testing is intended and supported for symptomatic patients.

    Billing Rule

    Applicable CPT/HCPCS codes — use listed codes for billing

    Use the applicable CPT/HCPCS and proprietary procedure codes listed in the policy when submitting claims; these codes serve as the billing/documentation references for the tests described in this policy.

    • Examples include CPT 81513 (molecular BV panel), CPTs 87480–87482 (Candida NAATs), 87510–87512 (Gardnerella NAATs), and 87660 (Trichomonas NAAT).
    • Procedure codes in the policy are provided for reference and may not be all‑inclusive.
    Prior Authorization

    Verify prior authorization for proprietary/molecular panels

    Verify payer prior authorization requirements for the specific molecular or proprietary panel test to be ordered (including listed CPT and proprietary U‑codes) before ordering.

    • Policy lists CPTs and proprietary codes (e.g., 0068U, 0330U, 0505U); check whether prior authorization is required for the specific test.
    Prior Authorization

    Minimum treatment window before repeat NAAT panel testing

    Do not repeat NAAT panel testing for the three vaginitis types (BV, VVC, trichomoniasis) before the minimum treatment window has passed; when symptoms persist despite treatment, individual organism testing may be performed within that window per guidance.

    • Note references CDC guidance that the longest minimum treatment (for trichomoniasis) is a seven‑day course and panels should not be repeated before that treatment window.
    Note

    Consider traditional diagnostics before molecular panels

    Consider lower‑cost traditional diagnostics (Amsel criteria, Nugent Gram stain, pH, KOH/amine test, wet mount microscopy, and point‑of‑care enzymatic tests) prior to ordering molecular panels when clinically appropriate.

    • CDC and policy text note traditional methods remain useful and lower cost, and may be sufficient in many symptomatic patients.
    Step Therapy

    Step therapy — none specified

    No step‑therapy requirements are specified in the policy sections provided.

    Billing Rule

    Procedure code reference — codes are for reference

    Procedure and proprietary codes listed in this policy are provided for reference and should be used when documenting ordered tests; they may not represent an exhaustive list of billable codes.

    • Providers should reference the policy’s CPT/HCPCS and proprietary identifiers when submitting claims.
    Documentation Required

    Symptomatic indication required — document signs/symptoms

    Coverage for diagnostic testing requires documentation of signs and symptoms consistent with vaginitis (e.g., vaginal discharge, odor, itch); document symptoms in the medical record when ordering NAAT or syndromic PCR panels.

    Documentation Required

    Clinical evaluation documentation — history, exam, basic tests

    Document a careful history and physical exam and, when available, basic in‑office laboratory testing (vaginal pH, KOH/amine test, microscopy/wet mount) before or when ordering molecular panels to support medical necessity.

    • Include information on sexual practices, menses, vaginal hygiene, prior self‑treatment, and other relevant history per CDC guidance.
    Documentation Required

    Document specimen type and symptomatic presentation

    Record the specimen collection method (clinician‑ or self‑collected vaginal swab) and confirm the specimen type is appropriate for the assay platform; also document that the patient is symptomatic.

    • FDA‑cleared assays (e.g., Aptima BV) specify clinician‑ or patient‑collected vaginal swabs for patients with a clinical presentation consistent with vaginitis.
    Billing Rule

    Procedure codes provided for reference — use appropriate codes on claims

    When documenting and billing, use the applicable CPT/HCPCS or proprietary test identifiers listed in the policy for the tests ordered; include these codes on claims as appropriate.

    Denial Risk

    Asymptomatic screening denied (including pregnant)

    Screening asymptomatic individuals (including asymptomatic pregnant persons at average or high risk for preterm labor) for trichomoniasis or BV does not meet coverage criteria and will be denied.

    • Routine screening of asymptomatic pregnant women for BV is not recommended by CDC/agencies and is not covered absent other risk factors.
    Denial Risk

    NAAT for Candida — not covered outside specified indications

    NAAT testing for Candida outside of the situations specifically described as covered (for example, broad quantitative Candida NAATs) does not meet coverage criteria and will be denied.

    Denial Risk

    Broad/multipurpose molecular panels are not covered

    Broad or multipurpose molecular panels intended for vaginal flora imbalance/infertility or panels that concurrently test for vaginitis and various other STIs are not covered and will be denied.

    • Policy explicitly states testing for microorganisms involved in vaginal flora imbalance/infertility and broad multiplex STI/vaginitis panels do not meet coverage criteria.
    Denial Risk

    BV NAATs require symptomatic indication

    Use of BV‑specific NAATs outside symptomatic women (i.e., for asymptomatic screening) is not supported and may lead to denial; ensure BV NAATs are ordered only for symptomatic patients.

    Denial Risk

    Multiplex NAATs intended for symptomatic patients only

    Multiplex NAATs and syndromic panels are intended for use in symptomatic patients; ordering these assays for asymptomatic individuals is not supported and may be non‑covered.

    Note

    Procedure code reminder — codes are general reference

    Procedure codes listed in the policy are included as general references and may not be all‑inclusive; verify coding and test identifiers for the specific assay when submitting claims.

    Testing Frequency and Repeat Intervals

    NAAT vaginitis panel testing — frequency limit
    Frequency limitNo more than one NAAT vaginitis panel test per 7 days (minimum interval: 7 days).
    Tests covered by limitApplies to NAAT panel testing designed to detect more than one type of vaginitis (e.g., BD MAX Vaginal Panel, NuSwab VG, Xpert Xpress MVP).
    Rationale/NotePer CDC-based guidance the minimum treatment window for organisms on panels (e.g., trichomoniasis) informs the 7-day repeat interval; repeat panel testing before this window is discouraged.
    Frequency limits — informational
    StatementNo explicit frequency limits stated in this document segment beyond panel-specific guidance elsewhere (see NAAT panel 7-day limit).
    ContextClinical utility and validity discussion does not specify additional repeat-interval constraints for individual tests.
    ImplicationFollow test-specific and coverage-section frequency rules rather than inferring new limits from clinical utility text.
    Trichomonas NAAT — retesting guidance
    Retesting recommendation for TrichomonasRetesting for T. vaginalis is recommended for all sexually active women approximately 3 months after initial treatment; earlier retesting is appropriate if symptoms recur.
    Treatment regimen contextCDC-recommended treatment for trichomoniasis is metronidazole 500 mg twice daily for 7 days; high reinfection rates motivate the 3-month retest.
    Clinical indicationPerform Trichomonas NAAT retesting as clinically indicated (persistent symptoms or suspected reinfection) within 3–12 months per CDC guidance.
    Frequency limits — additional notes
    SummaryNo additional frequency notes provided in this segment of the document.
    ActionRefer to the main Frequency Limits section or test-specific guidance for any other repeat-interval requirements.
    Coding noteProcedure codes listed are for reference and may not imply frequency constraints beyond policy text.

    Ordering Requirements and Specimen Guidance

    Note

    Order tests only for symptomatic individuals

    Testing is covered only for individuals with signs and symptoms of vaginitis; asymptomatic screening does not meet coverage criteria.

    Documentation Required

    Order NAAT panels after documenting history and exam

    Order molecular/NAAT panels for symptomatic patients after documenting history, examination, and basic office tests as available; CDC guidance supports molecular tests when in‑office microscopy or pH/KOH testing are unavailable or as adjuncts.

    Documentation Required

    Specimen and co-ordering requirements for NAAT panels

    Order molecular panels only when the patient is symptomatic; specimen may be a clinician‑ or validated self‑collected vaginal swab, and providers should co‑order other tests (pH, KOH, microscopy) as appropriate.

    • Confirm that the specimen type is validated for the assay platform used.
    • Co-order other tests when clinically indicated.
    Note

    No ordering provider restrictions stated

    The policy sections provided do not specify any restrictions on which provider types may order these tests.

    Background and Clinical Context

    Vaginitis is inflammation of the vagina presenting commonly with vaginal discharge, odor, itching, or discomfort. The most frequent infectious causes are bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis. Because symptoms overlap, laboratory testing (pH, amine test, wet mount microscopy, sialidase activity assays, culture, or NAAT) aids targeted therapy and accurate diagnosis.

    Definitions and Test Terms

    Definition — NAAT
    DefinitionNAAT: Nucleic acid amplification testing; molecular methods that detect specific DNA or RNA targets to identify infectious organisms.
    Common platformsIncludes PCR, TMA, and other amplification technologies used for detection and quantitation of nucleic acid markers.
    Specimen typesCommonly performed on clinician- or self-collected vaginal swabs for vaginitis testing.
    Definition — VVC
    DefinitionVVC: Vulvovaginal candidiasis — symptomatic infection of the vagina most commonly caused by Candida albicans; accounts for approximately one-third of vaginitis cases.
    DiagnosisDiagnosis may be by visualization of spores/hyphae on wet mount, vaginal fungal culture, or commercial diagnostic tests as recommended by ACOG.
    Clinical contextConsider culture or PCR for complicated or recurrent VVC to identify non-albicans Candida species.
    Definition — BV
    DefinitionBV: Bacterial vaginosis — a shift from Lactobacillus-dominant vaginal flora to overgrowth of Gardnerella vaginalis and anaerobic organisms associated with BV.
    Etiologic organismsMay include Gardnerella vaginalis, Atopobium vaginae, BVAB2, Megasphaera, and other anaerobes contributing to flora imbalance.
    Clinical importanceLaboratory testing assists targeted therapy because symptoms overlap between BV and other causes of vaginitis.
    Definition — Amsel criteria
    DefinitionAmsel criteria: Clinical diagnostic criteria for BV requiring at least three of the following: homogeneous thin discharge, vaginal pH >4.5, positive amine (KOH) test, and presence of clue cells on wet mount.
    UseWidely used clinical diagnostic method with sensitivity ranging broadly; recommended by CDC and ACOG as an acceptable diagnostic approach.
    RolePractical office-based method; microscopy availability can affect reliance on Amsel criteria versus molecular testing.
    Definition — Nugent score
    DefinitionNugent score: A Gram stain–based scoring system using vaginal swab microscopy to diagnose BV by quantifying bacterial morphotypes.
    PerformanceUsed as a laboratory standard comparator for BV diagnosis; often paired with Amsel criteria in studies and guidelines.
    ContextRequires laboratory microscopy and Gram staining; considered more objective than clinical criteria alone.
    Definition — Amsel criteria / Nugent score (combined)
    DefinitionAmsel criteria / Nugent score: Clinical (Amsel) criteria and Nugent Gram-stain scoring are complementary methods used as reference comparators for BV diagnosis.
    Guideline stanceCDC recommends BV can be diagnosed by Amsel criteria or Nugent score; both are accepted diagnostic approaches.
    Testing implicationsWhen microscopy is unavailable, molecular diagnostic methods (NAATs) may be used to confirm clinical suspicion.
    Definition — Multiplex NAATs (vaginal panels)
    DefinitionMultiplex NAATs (vaginal panels): Molecular assays that detect multiple bacterial and/or fungal targets (e.g., Gardnerella vaginalis, Atopobium vaginae, BVAB2, Megasphaera type 1, Lactobacillus species, Candida spp., Trichomonas) from a single vaginal swab.
    PerformanceSeveral assays (e.g., BD Max Vaginal Panel, Aptima BV, NuSwab VG, OneSwab BV) demonstrate high sensitivity and specificity and may provide algorithmic BV likelihood results.
    Intended useIntended for symptomatic women; some are FDA-cleared (BD Max, Aptima BV) while others are laboratory-developed tests.
    Definition — Molecular NAAT/PCR panels for vaginitis
    DefinitionMolecular NAAT/PCR panels for vaginitis: Panel tests (e.g., CPT 81513 and various U-codes) that detect DNA/RNA markers for organisms associated with BV and vaginitis and report results per organism or by algorithm.
    CPT exampleCPT 81513: quantitative real-time amplification of RNA/DNA markers for BV-associated organisms with algorithm reported as positive/negative for BV; panels may also include separate detection of Trichomonas and Candida species.
    ReportingResults commonly reported as detected/not detected per organism or as an algorithm-derived likelihood of BV, depending on the assay.

    Policy Revision History